PROFITELLIGENCE/Guest access
!
Financial disclaimer

Profitelligence provides financial data and analytics for informational purposes only. Nothing on this platform constitutes investment advice, a recommendation, or an offer to buy or sell any securities. Past performance does not guarantee future results. Always do your own research and consult a licensed financial advisor before making investment decisions.

Legal agreement

By continuing, you acknowledge that you have read and agree to our Terms of Service and Privacy Policy.

i
Guest mode

You're browsing as a guest. Some features like watchlists and alerts require a free account.

--:--:--
Guest mode— viewing ILMN. Sign up free to access all symbols.Sign up
ILMN logo

ILMN

Illumina, Inc.

HealthcareDiagnostics & Research

Price performance

Sep 18, 2026
$239.62
$5.56-2.27%
1M
+16.89%
3M
+47.98%
YTD
+78.36%
vs SPY
+12.49%
30d range
187–249
Volatility
50.53%
Signals
Price chart

Company activity

46 events
Company activity
TimeTickerTypeEventQtyPriceValue
08/17ILMN8-KIllumina, Inc. Completes Issuance of $300 Million in New Notes
08/13ILMN8-KIllumina Enters into New $1 Billion Credit Agreement
08/12ILMN8-KIllumina Announces $300M Notes Issuance
08/07ILMN8-KIllumina Settles GRAIL Acquisition Lawsuit with Mutual Releases
07/30ILMN8-KIllumina Reports Q2 2026 Financial Results and Updates Guidance
06/23ILMN8-KIllumina Appoints Dr. Daniel Skovronsky to Board of Directors
05/26ILMN8-KIllumina, Inc. Announces Results of 2026 Annual Meeting of Stockholders
04/30ILMN8-KIllumina Announces Strong Q1 2026 Financial Results and New Share Repurchase Program
04/02ILMN8-KIllumina Nominates David P. King to Board of Directors
02/05ILMN8-KIllumina Reports Q4 and FY 2025 Financial Results
01/30ILMN8-KIllumina Completes Acquisition of SomaLogic to Expand Proteomics Capabilities
01/13ILMN8-KIllumina Announces Preliminary Financial Results for Q4 and FY 2025
01/08ILMN8-KIllumina Appoints New Chief Medical Officer and Announces Departure of Chief Commercial Officer
11/25/25ILMN8-KIllumina Completes $500M Notes Offering
11/12/25ILMN8-KIllumina Announces $500 Million Notes Issuance
10/30/25ILMN8-KIllumina Reports Q3 2025 Financial Results and Updates Guidance
07/31/25ILMN8-KIllumina Reports Q2 2025 Financial Results and Provides Updated Fiscal Year Guidance
06/23/25ILMN8-KIllumina Announces Acquisition of SomaLogic
05/23/25ILMN8-KIllumina, Inc. Annual Meeting Results
05/08/25ILMN8-KIllumina, Inc. Announces First Quarter 2025 Financial Results
03/25/25ILMN8-KIllumina Appoints New Board Chair and Director, Director Resignation
03/24/25ILMN8-KIllumina, Inc. Announces Retirement of Chief Information Officer
03/10/25ILMN8-KIllumina Announces Fiscal Year 2025 Guidance and Cost Reductions Amid China Export Ban
02/06/25ILMN8-KIllumina Reports Q4 and FY 2024 Financial Results
01/14/25ILMN8-KIllumina Announces Preliminary Financial Results for Q4 and FY 2024
01/14/25ILMN8-KIllumina, Inc. Announces Further Real Estate Impairment Charges
11/04/24ILMN8-KIllumina Reports Third Quarter 2024 Financial Results
10/03/24ILMN8-KIllumina Announces Departure of General Counsel and Secretary
09/09/24ILMN8-KIllumina, Inc. Terminates Credit Agreement and Issues New Notes
09/05/24ILMN8-KIllumina Announces $500 Million Note Offering
08/06/24ILMN8-KIllumina Announces Q2 2024 Financial Results and Lowered FY 2024 Guidance
06/27/24ILMN8-KIllumina, Inc. Announces $1.9 Billion Impairment Charge for GRAIL Spin-Off
06/27/24ILMN8-KIllumina Completes Spin-Off of GRAIL and Releases Pro Forma Financials
06/24/24ILMN8-KIllumina Completes GRAIL Spin-Off
06/17/24ILMN8-KIllumina Announces New Credit Agreement
06/06/24ILMN8-KIllumina Announces Spin-Off Distribution Dates for GRAIL Shares
06/03/24ILMN8-KIllumina Announces Spin-Off of GRAIL and Associated Costs
05/20/24ILMN8-KIllumina, Inc. Announces Stockholder Approvals at 2024 Annual Meeting
05/03/24ILMN8-KIllumina, Inc. records $75 million in impairment charges due to facility exit
05/02/24ILMN8-KIllumina Reports First Quarter 2024 Financial Results
04/12/24ILMN8-KIllumina Announces EC Approval of GRAIL Divestment Plan
04/09/24ILMN8-KIllumina Announces New CFO and Strategic Officer Appointments
02/08/24ILMN8-KIllumina Announces Q4 and FY 2023 Financial Results with Goodwill Impairment
01/09/24ILMN8-KIllumina Announces Preliminary Financial Results for Q4 and FY 2023
01/09/24ILMN8-KIllumina, Inc. Announces Estimated Impairment Charges of $43M Related to Foster City Campus Exit
01/04/24ILMN8-KIllumina Appoints Interim Chief Commercial Officer Following Departure of Susan Tousi

ILMN filing record

Illumina, Inc. (ILMN): 46 8-K filings summarized, the most recent on Aug 17, 2026.

What the 8-K filings said

  1. Aug 17, 2026 · medium impact

    On August 17, 2026, Illumina, Inc. completed the issuance of $300,000,000 aggregate principal amount of its 4.950% notes due 2029. The company intends to use the net proceeds, along with cash on hand, to repay its 4.650% notes due September 9, 2026. The new notes will accrue interest at a rate of 4.950% per annum…

    Illumina, Inc. Completes Issuance of $300 Million in New Notes
  2. Aug 13, 2026 · medium impact

    Illumina, Inc. has entered into a new $1 billion senior unsecured five-year revolving credit facility, replacing its existing credit agreement. The new Credit Agreement provides for a variable interest rate and includes financial and operating covenants. The new facility matures on August 13, 2031, with an option for…

    Illumina Enters into New $1 Billion Credit Agreement
  3. Aug 12, 2026 · medium impact

    On August 10, 2026, Illumina, Inc. entered into an Underwriting Agreement for the issuance of $300,000,000 aggregate principal amount of its 4.950% notes due 2029. The offering is expected to close on August 17, 2026, subject to customary closing conditions. Illumina plans to use the net proceeds, together with cash…

    Illumina Announces $300M Notes Issuance
  4. Aug 7, 2026 · high impact

    Illumina, Inc. has entered into a Release Agreement to settle a lawsuit related to its acquisition of GRAIL, Inc. The lawsuit, filed by Icahn Partners LP, et al., will be dismissed with prejudice as to the plaintiffs only, without affecting other stockholders or related derivative actions. The settlement involves…

    Illumina Settles GRAIL Acquisition Lawsuit with Mutual Releases
  5. Jul 30, 2026 · high impact

    Illumina, Inc. reported financial results for the second quarter of fiscal year 2026, showing a 9.5% increase in revenue to $1.16 billion. The company reported GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5%. GAAP diluted EPS was $1.35, and non-GAAP diluted EPS was $1.31. Illumina updated its…

    Illumina Reports Q2 2026 Financial Results and Updates Guidance

SEC filings in the last five years

  • 66 Form 8-K
  • 13 Form 10-Q
  • 11 Form 8-K/A
  • 5 Form 10-K